Imatinib Mesylate in Treating Patients With Myelofibrosis

Sponsor

National Cancer Institute (NCI) (NIH)

Overall Status

Completed

CT.gov ID

NCT00039416

Collaborator

(none)

Enrollment

Location

Arm

Study Details

Study Description

Brief Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have myelofibrosis. Imatinib mesylate may stop the growth of myelofibrosis by blocking certain enzymes necessary for cell growth.

Condition or Disease	Intervention/Treatment	Phase
Chronic Myelomonocytic Leukemia Essential Thrombocythemia Polycythemia Vera Primary Myelofibrosis	Drug: imatinib mesylate Other: laboratory biomarker analysis	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

To determine the response rate (complete and partial) to STI-571 in patients with myelofibrosis.
To determine the safety of STI-571 in patients with myelofibrosis.

SECONDARY OBJECTIVES:

To determine the effects of STI-571 on bone marrow morphology (including effects on marrow fibrosis, osteosclerosis and cellularity) in patients with myelofibrosis.
To assess the effects of STI-571 on surrogate biologic endpoints including PDGFR expression (by immunohistochemistry), PDGFR signaling, and circulating progenitor (CD34 positive) cells.
To determine the effects of STI-571 on bone marrow cytogenetics in patients with an abnormal karyotype.

OUTLINE: This is a multicenter study. Patients are stratified according to Dupriez risk score (low vs intermediate vs high).

Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.

Study Design

Study Type:

Interventional

Actual Enrollment :

18 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis

Study Start Date :

Apr 1, 2002

Actual Primary Completion Date :

Aug 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (imatinib mesylate) Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.	Drug: imatinib mesylate Given orally Other Names: CGP 57148 Gleevec Glivec Other: laboratory biomarker analysis Correlative studies

Arm

Intervention/Treatment

Experimental: Treatment (imatinib mesylate)

Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.

Drug: imatinib mesylate

Given orally

Other Names:

CGP 57148

Gleevec

Glivec

Other: laboratory biomarker analysis

Correlative studies

Outcome Measures

Primary Outcome Measures

Clinical responses in terms of improvement in anemia and splenomegaly as previously published for myelofibrosis [Up to 12 months]
Frequency of adverse events graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0 [Up to 12 months]
Exact 95% confidence intervals generated using the binomial distribution.

Secondary Outcome Measures

Progression-free survival [Up to 12 months]
Analyzed using the Kaplan-Meier method.
Bone marrow response [Up to 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must have histologic confirmation of one of the following diseases-
Myeloid metaplasia with myelofibrosis (this includes all subtypes- chronic idiopathic myelofibrosis or agnogenic myeloid metaplasia, post thrombocythemic and post polycythemic myelofibrosis) or
Chronic myelomonocytic leukemia (CMMOL) with t(5;12)(q31-33;p12) or TEL-PDGFRβ rearrangement; patients with CMMOL and the t(5;7)(q31-33;q11.2) or other chromosomal translocations resulting in activation of PDGFR will also be eligible
Patients must have anemia (hemoglobin < 11 g/dL) or palpable splenomegaly (measured in cm from costal margin- to eligible); patients with palpable splenomegaly must have spleen size documented ultrasonographically as well; they must also meet standard diagnostic criteria for MMM* or CMMOL; patients with MMM must have thrombocytopenia (platelet count < 100 x 10^9/L) to be eligible; they must be Philadelphia chromosome or (BCR/ABL) rearrangement negative
Patients with CMMOL must also have the t(5;12)(q31-33;p12) or TEL-PDGFRβ rearrangement to be eligible
The Italian diagnostic criteria for MMM
Necessary criteria
Diffuse bone marrow fibrosis
Absence of the Philadelphia chromosome or BCR-ABL rearrangement in peripheral blood cells
Optional criteria
Splenomegaly of any grade
Anisopoikilocytosis with tear drop erythrocytes
Presence of circulating immature myeloid cells
Presence of circulating erythroblasts
Presence of clusters of megakaryoblasts and anomalous megakaryocytes in bone marrow sections
Myeloid metaplasia
Diagnosis of MMM is acceptable if the following combinations are present
The two necessary criteria plus any other two optional criteria when splenomegaly is present OR
The two necessary criteria plus any other four optional criteria when splenomegaly is absent
Patients may have had prior chemotherapy or radiation therapy including splenic irradiation; prior therapy with erythropoietin, GCSF or androgenic steroids is also permitted; there is no limit to number of prior regimens received; at least 4 weeks must have elapsed since prior chemo, radiation or other therapy
ECOG performance status =< 2 (Karnofsky >= 60%)
Total bilirubin < 1.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal unless due to disease
Serum creatinine < 2 X institutional upper limit of normal
Patients must not be pregnant or nursing because STI-571 at the recommended therapeutic dose may be harmful to the developing fetus or newborn; for this reason women of child-bearing potential and men must agree to use an effective contraceptive method; women of reproductive potential must have a negative pregnancy test within 7 days prior to registration; since interactions with oral contraceptives cannot be excluded at present, male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug
Ability to understand and the willingness to sign a written informed consent document
World Health Organization (WHO) diagnostic criteria for CMMOL:
Persistent peripheral blood monocytosis > 1 x 10^9/L
Absence of the Philadelphia chromosome or BCR/ABL fusion gene
Fewer than 20% blasts in the blood or bone marrow
Dysplasia in one or more myeloid lineages; if myelodysplasia is absent or minimal, the diagnosis of CMML may still be made if the other criteria (1-3) are met and:
An acquired clonal cytogenetic abnormality is present in the marrow cells
The monocytosis has been persistent for at least 3 months
Other causes for monocytosis have been excluded

Exclusion Criteria:

Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
Patients may not be receiving any other investigational agents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to STI-571
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study because STI-571 is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with STI-571, STI-571 should not be administered patients who are breastfeeding
HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with STI-571; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated
Because warfarin is metabolized through the CYP450 system, and since gastrointestinal bleeding may occur with STI-571, no therapeutic anticoagulation with warfarin will be permitted in patients participating in this study; as an alternative, therapeutic anticoagulation may be accomplished using low-molecular weight heparin (e.g. Lovenox) or heparin